Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maintenance therapy for chronic hepatitis C.

T Barry Kelleher1, Nezam Afdhal

  • 1Department of Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 8E, Boston, MA 02115, USA.

Current Gastroenterology Reports
|February 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case report and mini-review: Sarcina ventriculi in the stomach of an 80-year-old female.

Diagnostic microbiology and infectious disease·2023
Same author

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Gut·2023
Same author

Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease.

The American journal of gastroenterology·2022
Same author

Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease.

Cell reports·2021
Same author

Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.

Hepatology (Baltimore, Md.)·2021
Same author

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.

Hepatology (Baltimore, Md.)·2021
Same journal

Management of Common Bile Duct Stones: Current Approaches and Evolving Endoscopic Strategies.

Current gastroenterology reports·2026
Same journal

Solitary Rectal Ulcer Syndrome Revisited: A Comprehensive Narrative Review.

Current gastroenterology reports·2026
Same journal

The Microbiome and Esophageal Disease: Where Are We Now?

Current gastroenterology reports·2026
Same journal

Fermented Durian Tempoyak as a Source of Probiotics for Colorectal Cancer Prevention through Gut Microbiome Modulation.

Current gastroenterology reports·2026
Same journal

A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.

Current gastroenterology reports·2026
Same journal

The Role of Endoscopic Ultrasound in the Diagnosis and Management of Congenital Gastrointestinal and Pancreaticobiliary Conditions.

Current gastroenterology reports·2026
See all related articles

Hepatitis C virus (HCV) treatment failures are common with current therapies. New strategies are needed to prevent disease progression and reduce HCV-related mortality.

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Significant advancements in Hepatitis C Virus (HCV) treatment have occurred since 1989.
  • Current standard therapy (pegylated interferon alfa and ribavirin) achieves sustained virologic response in just over 50% of patients.
  • An estimated 2.7 million Americans have active HCV infection, leading to a substantial number of treatment failures.

Purpose of the Study:

  • To review the current landscape of HCV treatment, focusing on treatment failures.
  • To discuss potential therapeutic options for patients who do not respond to standard therapy.
  • To highlight the importance of preventing disease progression in the context of limited organ transplantation availability.

Main Methods:

  • Review of existing literature on HCV treatment efficacy and outcomes.

Related Experiment Videos

  • Analysis of current treatment guidelines and FDA-approved therapies.
  • Discussion of emerging strategies for managing HCV treatment failures and advanced disease.

    • Main Results:

    • Current optimal therapy for HCV yields sustained virologic response rates slightly exceeding 50%.
    • No FDA-approved therapies exist for patients who fail pegylated interferon alfa and ribavirin treatment.
    • Maintenance interferon therapy is a potential option for HCV treatment failures with advanced disease, aiming to prevent progression.

    Conclusions:

    • Preventing disease progression and decompensation is critical for managing the predicted burden of HCV morbidity and mortality.
    • Alternative medical strategies targeting hepatic fibrosis are under investigation.
    • Further research and therapeutic development are essential for addressing the unmet needs in HCV treatment failure management.